NEW APPROACHES TO BRAIN TUMOR THERAPY--A CNS CONSORTIUM

描述：（申请人的描述） 这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。 这将是 通过对有前景的新药进行的1/11临床评价， 生物学方法，以及治疗中的管理根源 原发性恶性肿瘤的中枢神经系统通过建立 的财团。 该联合体专门设计用于将联合收割机和 聚焦十三届优秀医疗资源和能力 机构对原发性脑肿瘤的影响。 为了实现这一目标， 财团将依靠其内部的特殊力量和能力， 每个参与机构和整个联合体内部。 的 宾夕法尼亚大学医学中心有1）大量的成年人 原发性脑肿瘤患者，2）专家多学科临床 3）广泛的临床和实验室检查， 研究人员，4）大量正在进行的高质量，临床 相关、同行评审和NIH资助的临床和实验室脑肿瘤 研究项目，5）国家认可的肿瘤学专业知识， 药理学、新药开发、I/II期临床试验， 神经外科和神经病理学，6）广泛的统计，数据管理， 和协调多机构研究，以及7）特殊 在临床护理和研究方面享有卓越的声誉。 该财团 将这些优势与一个定义明确、运作顺畅的 组织结构，强调临床试验设计、方案 开发、质量控制、研究监查和数据管理， 分析. 本方案的次要长期目标是使用此 共享人类脑肿瘤标本以及其他临床 和实验室数据，以收集有关1） 原发性脑肿瘤的基础生物学，2）新的神经药理学 治疗原发性脑肿瘤，3）改善护理和质量 成年人原发性脑肿瘤患者的生活。 这一目标将会实现 利用参与机构和NABTT的优势 相关生物学研究中心，NABTT药理学中心， NABTT在科学委员会工作。

DESCRIPTION: (Applicant's Description) The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by P h a se 1/11 clinical evaluations of promising new agents, biological a p proaches, and roots of administration in the treatment of primary malignancies of the central nervous system through the establishment of the consortium. This consortium is specifically designed to combine and focus experienced resources and capabilities of thirteen Outstanding medical institutions to bear on primary brain tumors. To meet this objective, the consortium will rely on the special strength and abilities that rest within each participating institution and within the consortium as a whole. The University of Pennsylvania Medical Center has 1) a large number of adult patients with primary brain tumors, 2) expert Mult-disciplinary clinical teams to care for these patients, 3) extensive clinical and laboratory researchers, 4) a striking number of on-going high quality, clinically relevant, peer reviewed and NIH funded clinical and laboratory brain tumor research projects, 5) nationally recognized expertise in Oncology, Pharmacology, new drug development, Phase I/II clinical trials, Neurosurgery, and Neuropathology, 6) extensive statistics, data management, and coordination of multi-institutional studies, and 7) exceptional reputation for excellence in clinical care and research. The consortium adds these strengths with a well defined and smoothly functioning organizational structure, and emphasis on clinical trial design, protocol development, quality control, study monitoring and data management and analysis. The secondary long-term objective of this protocol is to use this consortium to share human brain tumor specimens as well as other clinical and laboratory data to collect additional research pertaining to 1) the basic biology of primary brain tumors, 2) the Neuropharmacology of new therapies for primary brain tumors, and 3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the participating institutions and the NABTT correlative biology research center, the NABTT pharmacology center, and the NABTT working in scientific committees.